Celltrion has received construction approval for a new finished pharmaceutical (DP) plant in Songdo, Incheon, from the Incheon Free Economic Zone Authority (IFEZ). The new DP plant, capable of producing approximately 8 million liquid vials per year, will be built near the existing Plant 1. The company plans to complete the new DP plant by the first half of next year and to start commercial production in 2027.
Company Information
Company
Celltrion
Location
Incheon, Seoul, South Korea
About
Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specialises in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. The company’s solutions include world-class monoclonal antibody biosimilars such as Remsima®, Truxima® and Herzuma®, providing broader patient access globally. Celltrion has also received U.S. FDA and EC approval for several products, enhancing its portfolio in the biopharmaceutical industry.
IncheonManufacturingBiotechnologyTherapeuticsPharmaceuticalBiopharma